Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma [Yahoo! Finance]
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight [Yahoo! Finance]
Allogene Therapeutics Announces Q2 Investor Conference Participation